Overview

Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)

Status:
Completed

Trial end date:
2009-12-01

Target enrollment:

Participant gender:

Summary

Diabetic retinopathy (DR) is an eye disease that can occur in people with diabetes and can cause poor vision or blindness. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study is examining the effect of various treatments on cardiovascular disease in people with diabetes. This current study will examine the effects of the ACCORD treatments on the progression of DR in people participating in the ACCORD study.

Phase:

Phase 3

Details

Lead Sponsor:

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator:

National Eye Institute (NEI)

Treatments:

Fenofibrate
Hypoglycemic Agents
Simvastatin